Thesis (Ph. D.)--University of Wisconsin--Madison, 1969. / Vita. Typescript. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Phosphorylation of the alpha-subunit of the eukaryotic initiation factor 2 (eIF2alpha) on Serine 51 (Ser51) is an early event associated with downregulation of protein synthesis at the level of translation and constitutes a potent mechanism to overcome various stress conditions. In mammals, four eIF2alpha-kinases PERK, PKR, HRI and GCN2, activated following specific stresses, have been involved in this process. Our laboratory has previously demonstrated that the adaptor protein Nck, composed only of Src homology domains and classically implicated in cell signaling by activated plasma membrane receptor tyrosine kinases, modulates translation through its interaction with the beta-subunit of the eukaryotic initiation factor 2 (eIF2beta). Moreover, we reported that Nck-1 overexpression antagonizes the inhibition of translation in endoplasmic reticulum stress condition and prevents the PERK-mediated phosphorylation of the alpha-subunit of eIF2 on Ser51. In this thesis, I demonstrate that the adaptor protein Nck-1 modulates eIF2alpha-kinase-mediated eIF2alphaSer51 phosphorylation in a specific manner. More particularly, I show that Nck-1 overexpression reduces eIF2alpha phosphorylation in conditions activating PKR or HRI as described previously for PERK. In contrast, I observe that overexpression of Nck-1 in mammalian cells fails to attenuate eIF2alphaSer51 phosphorylation in response to amino acid starvation, a stress condition activating GCN2. I further confirm this observation by showing that Nck-1 fails to alter eIF2alphaSer51 phosphorylation in Saccharomyces cerevisiae, for which the sole eIF2alpha-kinase is GCN2. In addition, I report that Nck-1 reduces PKR activation in response to dsRNA. I also find that Nck-1 reduces dsRNA-induced activation of p38 MAPK, a PKR-downstream substrate, and cell death. Finally, I show that Nck-1 interacts exclusively with the inactivated form of PKR in a Src homology domain independent manner. All together these data uncover the existence of a novel mechanism regulating phosphorylation of eIF2alphaSer51 under various stress conditions and identifies Nck-1 as a modulator of the tumor suppressor and antiviral protein kinase PKR.

Cette thèse étudie le remodelage métabolique des cellules cancéreuses. Trois modèles sont analysés par de nombreuses approches biochimiques et génétiques : (i) des cellules de poumon transduites avec une forme oncogénique de HRASG12V, (ii) des cellules HeLa soumises à une privation de glucose et (iii) des pièces chirurgicales de cancer du poumon. Sur chaque modèle, le remodelage métabolique observé met en jeu de nombreuses voies du catabolisme et de l’anabolisme, notamment la glutaminolyse et la biosynthèse de sérine. Ce travail révèle un rôle important des mitochondries dans ce remodelage, à la fois pour l’apport d’énergie et pour la synthèse d’antioxydants et d’acides aminés, mais aussi de phospholipides. J’ai montré l’impact étendu d’une simple mutation HRASG12V sur un très grand nombre de processus, révélant ainsi l’importance de la génétique dans le remodelage métabolique des cellules cancéreuses. Toutefois, la privation de glucose induit elle aussi un remarquable remodelage à de très nombreux niveaux, depuis l’épissage des ARN messagers jusqu’à la synthèse de sérine. Enfin, cette thèse identifie deux classes bioénergétiques de tumeurs du poumon, ouvrant de nombreuses perspectives pour le diagnostic et la compréhension de ce type de tumeurs, mais aussi pour proposer des stratégies thérapeutiques adaptées. Les résultats identifient des biomarqueurs et des cibles validées sur nos modèles in vitro. Les perspectives de cette thèse vont consister à la transposition de ces approches à la clinique. / This thesis investigates the metabolic remodeling of cancer cells. Three models are analyzed by different biochemical and genetic approaches: (i) lung cells transduced with oncogenic HRASG12V, (ii) HeLa cells challenged with glucose deprivation and (iii) surgical pieces of lung tumors. On each model the observed metabolic remodeling involves numerous catabolic and anabolic pathways, including glutaminolysis and serine biosynthesis. Our work revealed an important role of mitochondria in metabolic remodeling, both for the supply of energy and for the synthesis of antioxidants and amino acids, but also phospholipids. We show the extent of a single mutation HRASG12V on a very large number of metabolic processes, revealing the importance of genetics in the metabolic remodeling of cancer cells. However, glucose deprivation also induced a remarkable remodeling at many levels of cell metabolism, from the splicing of messenger RNAs to serine biosynthesis. In the third part, this thesis identified two bioenergetic classes of lung tumors, opening interesting opportunities for the diagnosis and understanding of this type of tumor, but also to propose appropriate therapeutic strategies. The results identify biomarkers and targets validated in our in vitro models. The outlook of this thesis will be to the implementation of these approaches in the clinic

No description available.

Myc transcriptionally regulates genes involved in processes such as cell proliferation, metabolism, differentiation, and angiogenesis.  MYC expression is deregulated in many types of human cancer; therefore discovering the mechanisms behind MYCs role in tumorigenesis is essential.  In this dissertation, I have focused on several Myc target genes, Spermidine synthase (Srm); Lactate dehydrogenase (Ldh); 3-phosphoglycerate dehydrogenase (Phgdh); Serine hydroxymethyltransferase (SHMT) 1 and 2; and Pim-3 (a member of the Pim family of serine/threonine kinases).  These enzymes play a role in various functions: Spermidine synthase (polyamine synthesis); Lactate dehydrogenase (glycolysis); Phgdh and Shmt (serine metabolism); and Pim-3 (cell signaling).  In order to elucidate the impact Myc over-expression has on metabolism in tumorigenesis, we use human cell lines, and transgenic mice as well as cell lines and tissues derived from these mice.  The impact of inhibition of these target genes on Myc-driven tumorigenesis was done by genetically inhibiting the target gene (using RNAi or mouse models) or inhibiting the protein with a chemical inhibitor.  Investigating these Myc target genes will help determine if inhibition of Myc target genes is a viable approach for chemotherapeutics, and under what conditions this inhibition may be the most valuable.  In paper I, we examine SRM; a highly expressed enzyme in the polyamine synthesis pathway that converts putrescine to spermidine, and is important for actively growing cells.  Genetic inhibition via RNAi against Srm, or chemical inhibition of Srm, resulted in decreased proliferation of B-cell tumor lines from transgenic mice in vitro.  In vivo treatment of λ-Myc transgenic mice with a chemical SRM inhibitor exhibited a significant chemopreventative effect on tumor formation. These results support previous findings that inhibition of polyamine synthesis pathway enzymes has a place in cancer therapy.  Many Myc target genes have been suggested as attractive targets in battling Myc-driven tumorigenesis.  Surprisingly in paper II, when we analyzed the inhibition of other Myc target genes, such as Ldh, Shmt, and Phgdh, we found that inhibition of these genes did not inhibit Myc-driven tumorigenesis to any significant degree. However, inhibition of Ldh, Phgdh and Shmt2 had a notable effect on in vitro Ras-driven transformation.  These findings suggest that chemotherapeutic inhibition of metabolic genes such as Ldh, Phgdh and Shmt2 may be effective in genetically defined settings, keeping in mind the oncogenic lesion behind the tumor.  The Pim kinase family consists of three serine/threonine kinases, Pim1-3.  In paper III, we found that Pim-3 is a direct Myc target gene and that Pim-3 expression is high in Burkitt Lymphoma samples taken from human patients, as well as spontaneously arising lymphomas from Myc transgenic mice. We also found that inhibition of Pim-3 using a pan-Pim kinase inhibitor, Pimi, in these spontaneously arising Myc lymphomas resulted in caspase independent cell death.  These results indicate that Pim kinase inhibition may be a potential chemotherapeutic strategy in human lymphomas that rely on Pim-3 kinase expression.